Profound Medical (PROF) Projected to Post Earnings on Thursday

Key Points

• Profound Medical is expected to release its Q2 2025 earnings on August 14, forecasting a loss of ($0.43) per share and revenue of $4.75 million.
• CEO Arun Swarup Menawat recently purchased over 12,000 shares of the company, increasing his holdings by 2.09%, which suggests confidence in the company's future.
• The stock has experienced notable volatility, with a 1-year high of $10.25 and a low of $3.89, and currently has a market capitalization of approximately $165.58 million.

Profound Medical (NASDAQ:PROF - Get Free Report) is expected to release its Q2 2025 earnings data after the market closes on Thursday, August 14th. Analysts expect Profound Medical to post earnings of ($0.43) per share and revenue of $4.75 million for the quarter.

Profound Medical (NASDAQ:PROF - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The business had revenue of $2.62 million during the quarter, compared to analysts' expectations of $4.78 million. Profound Medical had a negative net margin of 269.35% and a negative return on equity of 70.41%. On average, analysts expect Profound Medical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Profound Medical Stock Performance

Shares of PROF stock traded down $0.13 during trading hours on Friday, hitting $5.54. The company's stock had a trading volume of 22,635 shares, compared to its average volume of 31,252. The company has a 50 day moving average of $5.93 and a 200 day moving average of $5.87. The stock has a market cap of $166.48 million, a PE ratio of -4.54 and a beta of 0.52. The company has a current ratio of 11.31, a quick ratio of 10.03 and a debt-to-equity ratio of 0.09. Profound Medical has a 12-month low of $3.89 and a 12-month high of $10.25.

Analyst Upgrades and Downgrades

Several research firms have recently commented on PROF. Raymond James Financial downgraded shares of Profound Medical from a "strong-buy" rating to a "moderate buy" rating in a report on Friday, May 9th. Lake Street Capital lowered their price target on shares of Profound Medical from $17.00 to $11.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd.

Insider Transactions at Profound Medical

In other news, CEO Arun Swarup Menawat purchased 12,027 shares of the stock in a transaction that occurred on Friday, May 16th. The shares were purchased at an average cost of $4.73 per share, with a total value of $56,887.71. Following the completion of the acquisition, the chief executive officer owned 587,089 shares of the company's stock, valued at approximately $2,776,930.97. This represents a 2.09% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.52% of the company's stock.

Institutional Trading of Profound Medical

An institutional investor recently raised its position in Profound Medical stock. Royal Bank of Canada raised its stake in shares of Profound Medical (NASDAQ:PROF - Free Report) by 3.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 435,997 shares of the company's stock after purchasing an additional 14,795 shares during the period. Royal Bank of Canada owned 1.45% of Profound Medical worth $2,537,000 at the end of the most recent quarter. 47.86% of the stock is owned by institutional investors and hedge funds.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.